Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication and its major protease in a non-competitive way
Otávio Augusto Chaves1,2,* , Carolina Q. Sacramento1,2 , Natalia Fintelman-Rodrigues1,2 , Jairo Ramos Temerozo3,4 , Filipe Pereira-Dutra1 , Daniella M. Mizurini5 , Robson Q. Monteiro5 , Leonardo Vazquez1,2 , Patricia T. Bozza1 , Hugo Caire Castro-Faria-Neto1 , Thiago Moreno L. Souza1,2,*
1Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, 21040-900, Brazil 2National Institute for Science and Technology on Innovation on Neglected Diseases (INCT/IDN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, 21040-900, Brazil 3National Institute for Science and Technology on Neuroimmunomodulation (INCT/NIM), Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, 21040-900, Brazil 4Laboratory on Thymus Research, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, 21040-900, Brazil 5Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, 21941-590, Brazil *Correspondence to:Otávio Augusto Chaves , Email:otavioaugustochaves@gmail.com Thiago Moreno L. Souza , Email:tmoreno@cdts.fiocruz.br
